Cross-institution positioning
Jul 27, 2026Mixed positioning. 1 accumulating, 1 exited across 2 comparable institutions.
Source: Schedule 13 researchANI PHARMACEUTICALS INC
Latest stored close $71.93 as of Oct 7, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Mixed positioning. 1 accumulating, 1 exited across 2 comparable institutions.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 0 purchases by 0 reporting owners and 11 sales by 5 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/53 non-amendment material events in the last 90 days; 1 capital-related filing/event (1 equity-related, 0 debt-related); Latest classified evidence: Director or executive change. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue +25.9% YoY; Net income +189.1% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 8% through its reported 52-week range; -27.0% over one year.
Source: Stored historical price seriesFiled Jul 27, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | CAREY STEPHEN P. | SOpen-market or private sale | Common Stock | 2.9K | $73.00 | Direct | Sep 30, 2026 |
| Sep 15, 2026 | Lalwani Nikhil | SOpen-market or private sale | Common Stock | 5.4K | $71.00 | Direct | Sep 16, 2026 |
| Sep 14, 2026 | Cook Meredith | SOpen-market or private sale | Common Stock | 500 | $70.79 | Direct | Sep 14, 2026 |
| Sep 11, 2026 | Thoma Jeanne | SOpen-market or private sale | Common Stock | 1.0K | $71.53 | Direct | Sep 14, 2026 |
| Aug 31, 2026 | CAREY STEPHEN P. | SOpen-market or private sale | Common Stock | 2.9K | $72.80 | Direct | Sep 1, 2026 |
| Aug 25, 2026 | Lalwani Nikhil | SOpen-market or private sale | Common Stock | 5.4K | $74.30 | Direct | Aug 26, 2026 |
| Aug 19, 2026 | Gosebruch Henry O | AGrant, award, or other acquisition | Common Stock | 6.7K | $0.00 | Direct | Aug 27, 2026 |
| Aug 13, 2026 | Cook Meredith | SOpen-market or private sale | Common Stock | 500 | $75.48 | Direct | Aug 13, 2026 |
| Aug 10, 2026 | Gutwerg Ori | SOpen-market or private sale | Common Stock | 3.2K | $77.00 | Direct | Aug 11, 2026 |
| Jul 29, 2026 | CAREY STEPHEN P. | SOpen-market or private sale | Common Stock | 2.9K | $81.36 | Direct | Jul 30, 2026 |
| Jul 18, 2026 | Cook Meredith | FTax/price withholding or payment | Common Stock | 2.5K | $79.20 | Direct | Jul 21, 2026 |
| Jul 13, 2026 | Cook Meredith | SOpen-market or private sale | Common Stock | 500 | $81.84 | Direct | Jul 14, 2026 |
| Jul 2, 2026 | CAREY STEPHEN P. | MExercise or conversion of derivative · derivative | Stock Option (right to buy) | 3.3K | $49.51 | Direct | Jul 6, 2026 |
| Jul 2, 2026 | CAREY STEPHEN P. | SOpen-market or private sale | Common Stock | 3.3K | $86.00 | Direct | Jul 6, 2026 |
| Jul 2, 2026 | CAREY STEPHEN P. | MExercise or conversion of derivative | Common Stock | 3.3K | $49.51 | Direct | Jul 6, 2026 |
| Jun 29, 2026 | CAREY STEPHEN P. | SOpen-market or private sale | Common Stock | 2.9K | $84.12 | Direct | Jun 30, 2026 |
| Apr 13, 2026 | Cook Meredith | SOpen-market or private sale | Common Stock | 500 | $77.95 | Direct | Apr 13, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Aug 24, 2026 | 8-K | 5.02, 9.01 | Director or executive change; Financial statements / exhibits | — | Filing |
| Aug 7, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Jul 17, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| May 21, 2026 | 8-K | 5.02, 5.07, 9.01 | Director or executive change; Shareholder vote results; Financial statements / exhibits | — | Filing |
| May 13, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| May 8, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $266.0M | +25.9% |
| Ended Jun 30, 2025 | $211.4M | — |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 27, 2026 filed · 27d Schedule 13G amendment | Reported accumulation | 2.9M +382.4K | 12.80% +0.80 pts | $82.78 | $78.37 | $71.93 |
| Vanguard Group CIK0000102909 | Mar 13, 2026 observed Mar 26, 2026 filed · 13d Schedule 13G amendment | Exit below reporting threshold | 0 -1.3M | 0.00% -6.31 pts | $70.49 | $74.14 | $71.93 |
| BlackRock CIK0002012383 | Sep 30, 2025 observed Oct 17, 2025 filed · 17d Schedule 13G amendment | Earliest Schedule 13G amendment found | 2.5M | 12.00% | $91.60 | $94.79 | $71.93 |
Compare ANIP with other securities showing similar institutional activity or recent accumulation across several tracked institutions.